

Development of CD5 CAR-NK therapeutics for treating NK and T-cell malignancies



ONCOLOGY	Phase 1
Product Type	Cell therapies / CAR-NK
Indication	NK and T-cell malignancies
Target	CD5
MoA(Mechanism of Action)	<p><i>Ex vivo</i> expanded, Genetically modified CAR-NK</p> <ul style="list-style-type: none"> • CAR (Chimeric antigen receptor) mediated tumor recognition • Direct cytotoxicity and Cytokine mediated cytotoxicity
Competitiveness	<ul style="list-style-type: none"> • Armed with 4th generation CAR to enhance target recognition, <i>in vivo</i> persistency and cytotoxicity • High purity and superior target-specific cytotoxicity • Allogeneic therapy: Off the shelf and lower cost • Better safety compared with CAR-T: <ul style="list-style-type: none"> Very low cytokine release syndrome and neurotoxicity • Low T cell aplasia, No fratricide and product contamination
Development Stage	Phase 1
Route of Administration	Intravenous